Director Michael Ellenbogen executed a paired option exercise and share sale in Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) on April 15, 2026.
On that date, Ellenbogen sold 80,745 shares of Class A Common Stock at a weighted average price of $6.32, producing total proceeds of $510,308. The sale prices ranged from $6.27 to $6.39.
Concurrently, Ellenbogen exercised option rights to acquire the identical number of shares - 80,745 - at an exercise price of $0.24 per share, for an aggregate cost of $19,378.
Following the exercise and sale, Ellenbogen’s reported direct ownership stands at 2,083,961 shares of Evolv Technologies Class A Common Stock. In addition, he indirectly holds 151,135 shares through the Family Horizon Trust.
The equity disposition was carried out under a Rule 10b5-1 trading plan that was put in place on June 12, 2025.
Company financials and recent commercial activity
Evolv Technologies disclosed fourth-quarter 2025 results showing revenue of $38.5 million, a 32% increase from the prior year and above the $36.43 million analysts had been modeling - a positive surprise of 5.68% versus consensus. Despite that top-line beat, the company reported a loss per share of $0.03 for the quarter, modestly wider than the expected loss of $0.02.
Separately, Evolv announced a multi-year renewal and expansion of its security screening agreement with Crypto.com Arena in Los Angeles. The extended deployment continues use of the Evolv Express screening solution and adds the new Evolv eXpedite bag-screening system. The arrangement was facilitated by AEG Global Partnerships and represents an extension of the arena’s original deployment.
Valuation context and available research
The director’s sale follows a period in which the stock returned roughly 95% over the past year. According to InvestingPro data cited alongside the transaction, the stock is trading above an assessed Fair Value of $4.86.
Investors looking for expanded analytics can reference the Pro Research Report on InvestingPro for deeper metrics and valuation context for EVLV and more than 1,400 other U.S. equities.
Takeaways
- The paired option exercise and share sale left Ellenbogen with substantial direct and indirect holdings in Evolv Technologies.
- Quarterly results showed revenue growth that beat expectations but also a slightly larger-than-forecast loss per share, highlighting an ongoing gap between top-line momentum and profitability.
- The company continues to expand commercial deployments, exemplified by the extended deal with Crypto.com Arena and the addition of the Evolv eXpedite system.